Is Summit Therapeutics a Millionaire Maker?
The pharmaceutical industry is often about hitting home runs. Big pharmaceutical companies start small, and then a blockbuster product catapults them into the spotlight. Summit Therapeutics (NASDAQ: SMMT) has soared 1,000% over the past year on progress in developing a drug that could rival Merck's Keytruda, a product used to treat various cancers with over $25 billion in sales last year.
Those who got in early have gotten rich. Is Summit Therapeutics still a potential millionaire maker?
Or have investors gotten too far ahead of themselves?
Source Fool.com


